MOESM1 of Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?

Additional file 1. Electronic Supplementary Materia

Paired samples analysis.

<p>A: Comparison of viral load in paired nasal swabs (NS) and bronchoalveolar lavage (BAL) samples. B: Distribution of 222 polymorphisms in paired NS and BAL specimens. NA, not available; ND, not done due to low viral load.</p

Prevalence of notable mutations in receptor binding sites, antigenic sites (Sa, Sb, Ca1, Ca2 and Cb) and amino acids fixed in each cluster among patient categories.

a<p>Amino acids numbering start after signal peptide DTLC.</p>b<p>P value>0.10 is considered not significant (ns); P value between 0.05 and 0.10 was considered a trend of significance; significant P value under 0.05 are in bold.</p>c<p>Data not available for all sequences.</p

MOESM1 of Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study

Additional file 1. Score and flow diagram for ECMO circuit change

Additional file 5: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

Table S4. Adjunctive measures/therapies during at least one day during follow-up in immunocompetent and immunocompromised patients. This table shows the proportions of adjunctive measures/therapies during at least one day during follow-up in immunocompetent and immunocompromised patients. (PDF 97 kb

Additional file 11: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

Table S7. Patient characteristics and clinical endpoints of immunocompetent patients, according to the type of ventilatory support. (PDF 88 kb

Additional file 12: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

Table S8. Patients’ characteristics and clinical endpoints of immunocompromised (study) patients, according to the cause of immunosuppression (known, unknown). (PDF 79 kb

Additional file 6: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

Table S6. Ventilator settings during the first day of ARDS in immunocompetent (Control) and immunocompromised (Study) patients, stratified by the type of ventilatory support (IMV, NIV, NIV failure). (PDF 60 kb

Additional file 8: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

Figure S2. This figure shows a Kaplan-Meier curve for hospital survival of immunocompromised patients according to the ventilation subgroup. This figure shows a Kaplan-Meier curve for hospital survival of immunocompromised patients according to the ventilation subgroup. Mortality is defined as mortality at hospital discharge or at 90 days after onset of acute hypoxemic respiratory failure, whichever event occurred first. We assumed that patients discharged alive from the hospital before 90 days were alive on day 90. Type of ventilator support: IMV Patients invasively ventilated from day 1, independently of the type of support received after the eventual extubation; NIV Patients treated exclusively with noninvasive ventilation, from day 1 to study exit, independently of outcome; NIV failure Patients initially treated with noninvasive ventilation and subsequently intubated during the study period. Note: The number of patients reported in the bottom of the figure is referred to as the end of the corresponding day. (PDF 396 kb

Additional file 9: of Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

Table S5. Factors associated with hospital mortality in immunocompromised patients. Multivariate logistic regression model describing the factors associated with hospital mortality in immunocompromised patients. (PDF 49 kb